In vivo suppressive effects of copoly(glycolic/L-lactic acid) microspheres containing CDDP on murine tumor cells

Journal of Controlled Release

Volumn 42, Issue 2, 1996, Pages 175-184

  Itoi, K ^a   Tabata, C Y ^b   Ike, O ^b   Shimizu, Y ^b   Kuwabara, M ^a   Kyo, M ^b   Hyon, S H ^b   Ikada, Y ^b  

^a Kansai Denryoku Hospital   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Biodegradable microsphere; Cisplatin; Copoly(glycolic L lactic acid); In vivo antitumor effects; Sustained release

Indexed keywords

CISPLATIN; DRUG CARRIER; MICROSPHERE; POLYGLACTIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES TUMOR; DRUG RELEASE; EVAPORATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SUSTAINED RELEASE PREPARATION; WEIGHT REDUCTION;

EID: 0030296186     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/0168-3659(96)01454-X     Document Type: Article

References (18)

1. [1] A.S. Weisberger and B. Levine, Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. J.A.M.A. 159 1955) 1704-1707.
2. [2] L.G. Suhrland and A.S. Weisberger, Intracavitary 5-Fluorouracil in malignant effusions. Arch. Intern. Med. 116 (1965) 431-433.
3. [3] M. Torisu, M. Katao, Y. Kimura, H. Itoh and M. Takesue, New approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival. Surgery 93 (1983) 375-364.
4. [4] J.S. Spratt, R.A. Adcock, M. Muskovin, W. Sherrill and J. McKeown, Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 40 (1980) 256-260.
5. [5] M. Maeta, S. Koga, N. Shimizu, R. Hamazoe, H. Kanayama, Y. Osaki and A. Izumi, Continuous hyperthermic peritoneal perfusion for peritoneal dissemination of gastric cancer. J. Jpn. Soc. Cancer Ther. 16 (1981) 1346-1350.
6. [6] S. Koga, R. Hamazoe, M. Maeta, N. Shimizu, H. Kanayama and Y. Osaki, Treatment of implanted peritoneal cancer in rats by continuous hyperthermic peritoneal perfusion in combination with an anticancer drug. Cancer 44 (1984) 1840-1842.
7. [7] M. Takahashi, Y. Koichi, I. Hiroshige, K. Kanji, M. Tetsuta, M. Yuichi and T. Masaru, The effect of intracavitary administration of an anticancer agent with glucocorticoid on cancer patients complicated with malignant effusion. J. Jpn. Soc. Cancer Ther. 18 (1983) 881-888.
8. [8] M.J.M. Deurloo, S. Bohlken, W. Kop, C.F. Lerk, W. Hennink, H. Bartelink and A.C. Begg, Intratumoral administration of cisplatin in slow-release devices. Tumour response and toxicity. Cancer Chemother. Pharmacol. 27 (1990) 135-140.
9. [9] B. Hecquet, C. Fournier, G. Depadt, P. Cappelaere, Preparation and release kinetics of microencapsulated cisplatin with ethylcellulose. J. Pharm. Pharmacol. 36 (1986) 803-807.
10. [10] M.J.M. Deurloo, W. Kop, O. Tellingen, H. Bartelink and A.C. Begg, Intratumoural administration of cisplatin in slow-release device. Pharmacokinetics and intratumoural distribution. Cancer Chemother. Pharmacol. 27 (1991) 347-353.
11. [11] A. Hagiwara, T. Takahashi, O. Kojima, T. Yamaguchi, T. Sasabe, M. Lee, C. Sakakura, S. Shoubayashi, Y. Ikada and S.H. Hyon, Pharmacologic effects of cisplatin microspheres on peritoneal carcinomatosis in rodents. Cancer 71 (1993) 844-850.
12. [12] M. Kyo, S.H. Hyon and Y. Ikada, Effects of preparation conditions of cisplatin-loaded microspheres on the in vitro release. J. Control. Release, 1995, in press.
13. [13] C.M. Riley, L.A. Sternson and A.J. Repta, High-performance liquid chromatography of cisplatin. J, Pharmaceut. Sci. 72 (1983) 351-355.
14. [14] R. Paolo and H.D. Walter, Multicenter evaluation of methods for counting residual white cells in leukocyte-depleted red blood cells. Vox. Sang. 66 (1994) 25-32.
15. [15] A. Hagiwara, T. Takahashi, T. Yamaguchi, H. Taniguchi, A. Iwamoto, C. Yoneyama, M. Itoh, T. Sasabe, M. Lee, R. Wada, S.H. Hyon and Y. Ikada, Intracavitary microspheres incorporating cisplatinum for the treatment of malignant effusions - clinical trials. Jpn. J. Cancer Chemother. 17 (1990) 1575-1578.
16. [16] F. Stewart, S. Bohlken, A. Begg and H. Bartelink, Renal damage in mice after treatment with cisplatinum alone or in combination with x-irradiation. Int. J. Radiation Oncology Biol. Phys. 12 (1986) 927-933.
17. [17] B. Drewinko, W.B. Brown and A.J. Gottlieb, The effect of cisdiammine-dichloroplatinum(II) on cultured human lymphoma cells and its therapeutic implications. Cancer Res. 33 (1973) 3091-3095.
18. [18] O. Ike, S. Hitomi, Y. Shimizu, R. Wada, S. Watanabe, S.H. Hyon and Y. Ikada, Administration of the adriamycin-containing poly(L-lactic acid) microsphere into the pleural cavity of patients with malignant pleural effusion. Drug Delivery Sys. 5 (1990) 23-27.